CN108348555B - 细胞扩增方法和治疗组合物 - Google Patents

细胞扩增方法和治疗组合物 Download PDF

Info

Publication number
CN108348555B
CN108348555B CN201680065321.7A CN201680065321A CN108348555B CN 108348555 B CN108348555 B CN 108348555B CN 201680065321 A CN201680065321 A CN 201680065321A CN 108348555 B CN108348555 B CN 108348555B
Authority
CN
China
Prior art keywords
mscs
cells
medium
culture
conditioned medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680065321.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108348555A (zh
Inventor
B·班纳吉
C·摩根
格雷厄姆·维赛
N·H·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Ideas Pty Ltd
Original Assignee
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903658A external-priority patent/AU2015903658A0/en
Application filed by Cell Ideas Pty Ltd filed Critical Cell Ideas Pty Ltd
Publication of CN108348555A publication Critical patent/CN108348555A/zh
Application granted granted Critical
Publication of CN108348555B publication Critical patent/CN108348555B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680065321.7A 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物 Expired - Fee Related CN108348555B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903658A AU2015903658A0 (en) 2015-09-08 Cell expansion methods and therapeutic compositions
AU2015903658 2015-09-08
PCT/AU2016/000316 WO2017041133A1 (en) 2015-09-08 2016-09-08 Cell expansion methods and therapeutic compositions

Publications (2)

Publication Number Publication Date
CN108348555A CN108348555A (zh) 2018-07-31
CN108348555B true CN108348555B (zh) 2022-07-08

Family

ID=58240422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680065321.7A Expired - Fee Related CN108348555B (zh) 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物

Country Status (10)

Country Link
US (2) US20180236003A1 (enExample)
EP (1) EP3347449A4 (enExample)
JP (3) JP6995752B2 (enExample)
KR (1) KR20180043834A (enExample)
CN (1) CN108348555B (enExample)
AU (1) AU2016321448B2 (enExample)
CA (1) CA3035931A1 (enExample)
HK (1) HK1252778A1 (enExample)
TW (1) TWI760313B (enExample)
WO (1) WO2017041133A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016342387B2 (en) * 2015-10-23 2021-12-09 Rigshospitalet Stem cell therapy based on adipose-derived stem cells
WO2018213795A1 (en) * 2017-05-18 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
CA3103043A1 (en) 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
CN109022360A (zh) * 2018-07-03 2018-12-18 湖南未名三胞转化医学科技有限公司 自体脂肪干细胞共培养促进外周血造血干细胞增殖方法
CN110106142B (zh) * 2019-05-30 2020-05-12 深圳阿尔法生物科技有限公司 一种制备“百亿”级脂肪源再生细胞的生产工艺
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
KR102193175B1 (ko) * 2020-04-07 2020-12-18 주식회사 엑소스템텍 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores
US20230365937A1 (en) * 2020-10-26 2023-11-16 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
BR102022016233A2 (pt) * 2022-08-16 2024-02-27 Omics Biotecnologia Animal Ltda Concentrado de proteínas e peptídeos derivados de células estromais mesenquimais, método de obtenção e uso de concentrado

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085421A2 (en) * 2004-03-02 2005-09-15 The University Of Manchester Treatment of spinal conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034803A1 (en) * 2006-09-18 2008-03-27 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
PL2611906T3 (pl) * 2010-08-31 2024-05-27 Gallant Pet, Inc. Ogólnoustrojowe terapie allogenicznymi komórkami macierzystymi do leczenia chorób u kotów i psów
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
US20140219972A1 (en) * 2013-02-05 2014-08-07 The Board Of Trustees Of The Leland Stanford Junior University Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
EP3405204B1 (en) * 2016-08-26 2025-06-25 Restem Llc Composition and methods of using umbilical cord lining stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085421A2 (en) * 2004-03-02 2005-09-15 The University Of Manchester Treatment of spinal conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Expired and Pathogen-Inactivated Platelet Concentrates Support Differentiation and Immunomodulation of Mesenchymal Stromal Cells in Culture;Sandra Mjoll Jonsdottir-Buch等;《Cell Transplant》;20140715;第24卷(第8期);第1545-1554页 *
Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture;G M van Buul等;《Osteoarthritis Cartilage》;20121001;第20卷(第10期);第1186-1196页 *
Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics;Julia P Vogel等;《Platelets》;20090707;第17卷(第7期);第462页摘要 *

Also Published As

Publication number Publication date
JP2022027928A (ja) 2022-02-14
HK1252778A1 (zh) 2019-05-31
TWI760313B (zh) 2022-04-11
KR20180043834A (ko) 2018-04-30
AU2016321448B2 (en) 2023-02-02
WO2017041133A1 (en) 2017-03-16
EP3347449A1 (en) 2018-07-18
US20210260129A1 (en) 2021-08-26
JP2022186992A (ja) 2022-12-15
AU2016321448A1 (en) 2018-03-15
CN108348555A (zh) 2018-07-31
US20180236003A1 (en) 2018-08-23
EP3347449A4 (en) 2019-03-20
JP6995752B2 (ja) 2022-02-04
CA3035931A1 (en) 2017-03-16
TW201720922A (zh) 2017-06-16
JP2018526447A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
CN108348555B (zh) 细胞扩增方法和治疗组合物
Al Naem et al. Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders
Dominici et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
CN105796600B (zh) 使用干细胞治疗骨关节炎的方法和组合物
Badowski et al. Mixed effects of long-term frozen storage on cord tissue stem cells
JP2010529987A5 (enExample)
Horak et al. Evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study
JP2010529987A (ja) ｉｎｖｉｔｒｏで培養および増殖させた自己複製性コロニー形成細胞を用いる疾患および障害の治療
WO2015137419A1 (ja) 間葉系幹細胞の賦活化剤、賦活化された間葉系幹細胞およびその製造方法
WO2011069121A1 (en) Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
WO2020061627A1 (en) Mesenchymal stem cells and products therefrom
US20210322644A1 (en) Biomaterial comprising adipose-derived stem cells and gelatin and method for producing the same
CN115125192B (zh) 一种骨髓上清液及其在细胞培养中的应用
Youngstrom et al. Cartilage-derived extracellular matrix extract promotes chondrocytic phenotype in three-dimensional tissue culture
US20180000869A1 (en) Amniotic fluid-derived preparations
US20130266542A1 (en) Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
WO2021011779A2 (en) Mesenchymal stem cell compositions
Leung et al. Osteochondral tissue engineering for osteoarthritis using infrapatellar fat-pad derived mesenchymal stem cells
EP4227406A1 (en) Method for stimulation of mesenchymal cells to induce immunomodulatory factor expression
TWI493035B (zh) Human umbilical cord mesenchymal stem cells in vitro culture method, promote cell growth and wound healing of the relevant components of the manufacturing method and its application.
Long et al. Establishing a mesenchymal stem cell bank from umbilical cord tissue for cell therapy and initial application in the treatment of knee osteoarthritis at Tam Anh general hospital
Sarel et al. FasL promotes proliferation and delays differentiation of ASCs
Coat PRP is derived from autologous venous blood. Blood is withdrawn from a patient’s vein, and centrifuged, inducing cell and platelet separation in suspension based on their den-sities. Fractionally, red blood cells (RBCs) are the heaviest and layer at the bottom, followed by white blood cells
RU2780179C2 (ru) Происходящие из перинатальной ткани мезенхимальные стволовые клетки: способ их получения и применения
Cormier et al. Office-Based Orthobiologic Procedures for Tendons

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220708

CF01 Termination of patent right due to non-payment of annual fee